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Introduction 
 
With the advent of crystallography to elucidate membrane protein 
structures, molecular repositories and software packages, computer 
simulations have become widely accepted to gain insight into 
biochemical processes on a molecular level, despite certain setbacks 
[1-5]. The binding models for liganded TLR4 ectodomain/MD-2 
complexes were generated and sequences and proteins aligned (Figure 
1 and Figure 2 in [6]). The scope of the present in silico study was 
then to elucidate structural and functional implications regarding the 
reported species-dependent - either antagonistic or weak agonistic -  
activity  profile  of  the  tetra-acylated   ligand  Lipid IVA  versus  the  
  
 
 
 
 
 
 
 
 
  
 
 
 
 
species-independent strong immunostimulatory activity of lipid A. 
Lipid A of the hexa-acylated enterobacerial type represents the central 
immunoactivating (endotoxic) substructure in lipopolysaccharides 
(LPS) as characterized for the majority of mammalian commensal 
Gram-negative bacteria [6,7]. In comparison to the lipid A and Lipid 
IVA structures the species-independent TLR4/MD-2 receptor 
antagonist Eritoran was analyzed in this in silico study. In total, 
structure-activity analyses of a receptor-ligand array composed of 
TLR4 ectdomain/MD-2 complexes from four mammalian species 
(man, mouse, horse and dog) and three ligands (lipid A, Lipid IVA 
and Eritoran) is presented here. 
Prior to work the literature was reviewed [6]. Escherichia coli-
type Lipid IVA activates murine macrophages but antagonizes LPS in 
human macrophages [7]. It is assumed that such agonistic and 
antagonistic activity changes for the very same ligand are embedded in 
TLR4/MD-2 sequence differences among mammalian species [8]. 
The innate immune system centrally consists of very effective 
recognition systems for detecting microbial and viral infections on the 
molecular level: binding of exogenic microbial or viral ligands at 
minute (picomolar) concentrations to specific immunoreceptors on 
the cell surface or in intracellular compartments leads to triggering of 
an effective immune-response [9]. Analytical laboratory work has 
been driven to the cutting edge of what can be achieved technically 
concerning isolation, purification and characterization. Due to 
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undetected contaminants when interpreting LPS and congeners 
activities it matters whether they are obtained from natural sources or 
in vitro synthesis [10-12].  
 
Methods 
 
In earlier publications, molecular modeling methods were applied 
and lent mechanistic insights [7,13-23]. Docking was conducted 
using Autodock 4.2 following the procedure introduced by Meng et 
al. 2010 [14]. In the following computational simulations it will be 
shown that ligand binding occurs in the wedge-shaped region between 
protein units where conserved amino acids and nonhomologous 
residue changes play a complicated concert of interactions all of which 
influence the phosphate binding in the interface between TLR4 and 
MD-2 or in the contact zone of a second TLR4/MD-2 unit leading 
to dimerization and signaling. Applying ligand docking into a model 
receptor with automated refinements is a straight forward approach to 
decipher species differences related to a given binding mechanism 
when homology between sequences is given and structural templates 
are known. The rationale for our selection of appropriate software 
was that Autodock’s original calibration set embraces relevant binding 
patterns for polar (hydrogen bonds, salt bridges) and hydrophobic 
interactions (alkyl groups) [24-27]. The bibliographic and 
experimental knowledge gained in earlier docking studies with Insight 
II, Ludi, FlexX, MOE and Autodock was an invaluable asset during 
work [4,5,28,29]. 
 
In order to visualize the degree of similarity (identity or 
homology) of amino acid sequences web-based CLUSTAL W [30, 
31] was used for multiple sequence alignments (MSA).  
 
Crystal structures were gathered (Table 3 in [6] and 
[18,19,21,22,32]) and served as 3D templates [1, 2, 11, 18, 19, 32, 
33] for homology protein modeling based on our published 
experience [34]. The ligands (lipid A, Lipid IVA and Eritoran) were 
build or extracted from structural data sources (Table 3 in [6] and 
[18,19,21,22,32]). The 3D structures of TLR4 and MD-2 models 
were build as homology models using Scwrl4 [35], with the same 3D 
template (PDB code 3FXI [18]).  
 
After multiple sequence alignment studies under Clustal W [30] 
side chain geometries of residues were either kept in case of identities 
or empirically recalculated into crystal-like conformations by Scwrl4 
[35]. Those residues were highlighted in the alignments and mapped 
onto the three-dimensional models which are known to be relevant 
[6]. The dog MD-2 protein has not yet been described experimentally 
(last visit March 2013, Universal Protein Resource at 
www.uniprot.org). Over a dozen Sybyl Programing Language scripts 
were written to associate the superposed 3D models with published 
data on important amino acids (FZB licenses during 2009-10) [36]. 
In the next step the interacting side chains of the computed ligand-
protein interfaces were compared with those from our CSBJ literature 
review [6].  
 
The initial ligand positions at the binding sites (Table 1) were 
generated using as main references PDB entries 3FXI (with bound 
LPS), 2E59 (with bound Lipid IVA), 2Z65 (with bound Eritoran) 
[18,19,21,32].  
We manually docked ligands into the unliganded complexes 
(user-attended docking) and refined interesting parts (glucosamine 
backbones with phosphate groups) under Autodock 4.2 (unattended 
docking) [24,25,37]. Ligands from known complexes were docked 
back into their observed poses while all other poses where computed 
in spatial proximity under the assumption that closely related 
structures should end up in similar binding modes [18,19,21,32]. 
Ligand-relevant amino acids of our three-dimensional models were 
computationally listed for inspection. The ligand’s atomic partial 
charges were calculated by the Gasteiger approach under VEGA ZZ 
[3,38] while the receptor TLR4/MD-2 complex was prepared under 
Autodock Tools for docking [37]. The torsion free energies were 
estimated. 
 
The established general view is that the observed ligand binding in 
the crystal complexes is based on hydrophobic interactions and 
hydrogen bonds on the one hand, and the electrostatic attraction of 
the phosphate groups on the other hand. This holds true, also, for the 
models which include fatty acid chains of the LPS and congeners 
binding deeply into the cleft of MD-2. Their affinities are influenced 
by noncovalent intermolecular interactions between the two molecules 
such as hydrogen bonding, electrostatic interactions, hydrophobic and 
van der Waals forces which can be estimated by computational means. 
Lipoglycans, however, are far from being drug-like, which is the 
prerequisite for successful application and parametrization of 
common docking programs like Autodock [24,37]. Hence, their 
utility as exploration tools for LPS investigations is fairly limited 
[4,5]. The particular challenge of LPS modeling is their pronounced 
amphiphilic nature: polar parts and ionic centers in addition to vast 
nonpolar and extremely flexible alkyl chains. Actually, the huge 
number of rotatable bonds is greatly reduced by coalescence 
phenomena of the fatty acid segments alone or upon binding in the 
hydrophobic cleft. The cohesion forces increase with higher fatty 
acids content and binding depth into the cleft. Hence the entropic 
quantities (water solvation and dissociation processes, conformational 
states) of LPS-like ligands must be considered during parametrization 
since they differ greatly from drug-like ligands. Particularly, by its 
theoretical nature of the in silico approach as introduced by Meng et 
al. 2010 [14] certain assumptions have to be drawn and other 
implications are related to embeddings under certain methodological 
operations and working hypotheses expressing awareness about 
implicit limitations to avoid overinterpretation (Table 2). A critical 
point in the docking procedure constitutes Autodock’s torsional free 
energy concept (TFE) [24]. TFE is a scaled value and only a crude 
estimate for torsion entropies. All of which constitutes a serious 
setback in cases of ligands with extended alkyl scaffold substitutions. 
TFE values tend to overemphasize the influence of rotatable bonds on 
acyl chains. With chain length increasing, alkyl chains tend to form a 
lipid bulk phase (random coil with a droplet-like shape) where much 
of the rotational freedom is lost. In a similar way, the aliphatic side 
chains of lipoglycans dock deeply into the hydrophobic binding 
pocket of MD-2. To this regard, underacylation and shorter acyl 
chains clearly have an impact. Not only that the hydrophobic contact 
zone in the MD-2 pocket is greatly reduced but also the tendency of 
phase coalescences diminishes, i.e. cohesion energies of fatty acids in 
both lipid pockets and droplets. 
 
 
TLR4 / MD-2 receptor complexes 
2 
Volume No: 7, Issue: 9, May 2013, e201305003 Computational and Structural Biotechnology Journal | www.csbj.org 
  
Results and Discussion 
 
Prior to the present molecular docking simulations to analyze the 
species-dependency of Lipid IVA activities, all known crystal 
structures were inspected and aligned (Figure 2 and Table 3 in [6] 
and [18,19,21,22,32]). Since Lipid IVA and Eritoran are structurally 
closely related to lipid A and LPS (Figure 1 in [6]), it can be assumed 
that they dock into the TLR4/MD-2 complex in a similar position 
and orientation as observed in LPS crystal complexes [18]. Hence, we 
choose the LPS pose as the start conformation for all docking runs 
concerning agonists and the crystal structural binding site positioning 
of Eritoran for the flipped orientation of antagonists [19]. In its most 
abstract and general form the 3D models devise a triangular interface 
(“wedge”) where molecular interactions with all ligands take place. 
The resulting differential amino acids of human, murine, equine and 
canine complexes of the TLR4/MD-2 receptors were identified and 
documented.  
 
As a direct result after aligning full sequences of  both proteins, 
the overall scores of  sequence identities can be compared (Table 3). It 
can be seen that murine sequences show lower similarity when 
compared to the other mammalian species analyzed in this study. This 
outcome appears to be a molecular reflection of  the mice immune 
system having evolved to respond to a special set of  commensal and 
environmental bacteria within the context of  the behavior, food and 
anatomic needs of  rodents as compared to the three other non-rodent 
species. Moreover, also when comparing the entire sequences, the 
human MD-2 and TLR4 proteins are more identical to horse than to 
mouse (Table 3).  
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The multiple sequence alignments (MSA) [30], reveal a striking 
uniqueness of  murine residues in certain positions of  the MD-2 as 
well as TLR4 sequences (Figure 1 and Figure 2). 
Due to nonidentical deletions over evolutionary time the residue 
numbers in the sequences differ slightly for equivalent positions: (1) 
for initial segments up to equine position 297: e=h=c=m+1, i.e. one 
early gap appears in the murine N-term segment; (2) from equine 
position 297 to 560: e = m+3 = h+1 = c+1 or h=m+2=e-1=c-1. 
Moreover, “a”, “b”, and “c” are shorthand suffixes to residue numbers 
in chains TLR4, counter TLR4* and MD-2, respectively, and were 
taken from 3FXI [18]. For instance, mGlu122c can be found as 
glutamate labeled E in the murine row at position 122 of  chain “c” 
(the MD-2 protein) in the last MSA block of  Figure 2. In the 
equivalent positions, the human, equine and canine sequences appear 
more closely interrelated than the corresponding mouse TLR4. The 
results are in line with published biochemical tests showing that Lipid 
IVA acts as an agonist in mouse, but as partial (or weak) agonist in 
horse and as antagonist in human cell test systems while Lipid IVA 
seems not to be an agonist of canine TLR4 [15,18-20,32]. For 
instance, the highest overall identity score (Table 3) is actually found 
between the dog and horse TLR4. The residues resembling in relevant 
sequence positions explain why Lipid IVA seems be an antagonist in 
both cases [20]. 
 
 
 
 
 
 
 
 
 
 
Figure 1. Multiple sequence alignment of the murine, human, equine and 
canine TLR4 sequences [18,30]. The TLR4 protein sequence identification 
number (gi of NCBI records) is given in addition to the species letter (h, c, 
m or e). A comment line above the sequence blocks refers to residues 
discussed in the text (underlined, bold face). The last line of a MSA block 
labels the homology relationship (full identity “*”; high similarity “:”; low 
similarity “.” while blank space marks missing homology). The residue 
numbers follow the equine length for being without gaps.  
 
Figure 2. Multiple sequence alignment of the murine, human and equine 
MD-2 sequences (chain c in 3FXI) [18,30]. The human sequence was 
extracted from the crystal structure [18] which served as the 3D template 
for the mouse and horse models. The canine sequence entry, however, is 
available as a theoretical prediction. A comment line above the MSA 
blocks refers to residues discussed in the text (underlined, bold face). 
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 Literature provides knowledge about the physico-chemical 
characteristics of  ring energy barriers, the preferred conformers, and 
the reactivity and dipole moments of  sugar moieties. For glycosidic 
bonds, the tendency to suffer hydroxylation is more pronounced under 
acidic conditions and the bonds tend to resist base attack. The two 
phosphate ester groups shield any acidic attack (e.g. adjacent acidic 
side chains of  residues) by negative charge repulsion. The dipole 
moment of  the substitution pattern of  the diglucosamine backbone 
was investigated to rule out any intramolecular dipolar repulsion effect 
since it is known to exist, for instance in the case of  trans-1,2-
dibromocyclohexane which is present in equatorial conformers in 
polar solvents, that means under dipole reinforcing environment. But, 
when exposed to nonpolar solvents, the same compound was reported 
to show both substituents in axial orientation and the dipole effect 
was canceled. Like their scaffold cyclohexane, monosaccharides and 
their derivatives predominantly adopt a chair conformation. On 
theoretical grounds chair-flipping (fast interconversation at room 
temperature) of  the unsubstituted diglucosamine backbone is possible 
to invert the axial and equatorial positions since the energy barriers of  
the cyclohexane scaffold are about 10 kcal/mol which can be 
overcome in a thermal bath at room temperature (threshold 10 to 20 
Kcal/mol). But in the case of  LPS due to numerous substitutions the 
chair flipping which has been experimentally observed for cyclohexane 
at room temperature should be greatly hindered and the resulting 
conformation with equatorial substitutions becomes predominant in 
practical terms (with an additive energy gain of  5 kcal/mol for a 
bulky substituent) [40,41].  
The normal and flipped orientation which was observed in 
liganded complexes was also dealt with during docking, see the study 
design in the Methods section (Table 1). When back docking ligand 
poses which can be observed in 3FXI [18] or 2E59 [32] Autodock 
could occasionally restore the proper orientation but not in the most 
populated RMSD clusters (i.e. groups of  geometrically similar 
conformations) of  final docked solutions. 
 
In Table 4, the activity-dependent binding patterns become 
obvious. The ligands are not exactly symmetrical when referring to 
their common diglucosamine backbone because one phosphate group 
is in equatorial (the ester-bound P2 of  GlcN2) and the other in axial 
position (the α-glycosidic P1 of  GlcN1), which is an important 
matter influencing their height above the MD-2 opening and their 
subunit linker capacity for complex dimerization. Apparently only in 
the “normal” agonistic orientation the phosphate groups can bridge 
and grasp both TLR4 subunits with sufficiently strong nonbonded 
forces to side chains of  TLR4 and counter TLR4*. Since the activity 
is not clear, the comparison with 3MU3 remains inconclusive (Table 
4 in [6] and [18,21,32]). 
 
The variable pocket sizes between MD-1 and MD-2 were 
discussed in the crystallographic literature [14,32]. While Yoon et al. 
observed an increase in pocket size for chicken MD-1 upon Lipid 
IVA binding, Ohto et al. reported no significant changes when Lipid 
IVA binds to human MD-2 [32]. The pocket of hMD-2 filled with 
an agonistic LPS molecule becomes somewhat larger than when 
occupied by antagonists like Lipid IVA or Eritoran which share a 
common binding mode with a horizontally flipped backbone 
compared to LPS due to side chain arrangements [8,18,32]. The alkyl 
chains are superposed for comparison in Figure 3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Schematic display of the rotated (´flipped´) cavity occupation in 
human MD-2 by acyl side chains of agonistic LPS (green) and antagonistic 
Lipid IVA (red), found in two crystal structures (PDB codes: 3FXI, 2E59) 
[18,32]. Cycles give the chain lengths. For instance, in LPS (green) four 
chains of (R)-3-hydroxytetradecanoic acid (green circles “14”) are attached 
to the backbone by either amide or ester bonds in positions A, B, C and D 
which corresponds to R2´, R2´´, R3´ and R3´´ in an alternative labeling 
convention [18] and the ´secondary´  lauryl (C12)  and myristoyl (C14) and 
residues are mapped in positions C´and D´, respectively. In Lipid IVA (red) 
there are only 4 chains, labeled A to D. Its chain D partially occupies the 
corresponding space of LPS chains A and C´ (green). The square boxes 
indicate the number of carbon atoms in a chain which are overlapping 
with an adjacent chain (superposition length). The side chains C and D of 
antagonists (red) are more deeply buried (see the relative location of the 
amide and ester head groups). 
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 In order to elucidate the reasons for the backbone flipping, 
docking simulations were carried out with ligands in observed and 
flipped starting poses (Table 5). Observed poses are taken from the 
cases of Lipid IVA and Eritoran. Rejecting docked poses was the 
result of bad Van der Waals contacts, i.e. atomic repulsion forces due 
to the lack of space to accommodate the ligand in the cavity at the 
binding site (Table 5).  
Only murine Lys367b can attract the phosphate group of  the 
ligand. In the human, dog and horse systems, however, the equivalently 
positioned residues are repulsive anionic (acidic) residues (glutamate 
or aspartate). Moreover, in human, canine and equine species a 
conserved lysine functionally “neutralizes” aforementioned glutamate 
or aspartate residues by forming salt bridges (equine position 389b in 
Figure 3 in [6], Tables 6 and 7). In mice, this position (equine 389b) 
is mSer386 (labeled 389b in Figure 1, Tables 6 and 7) leaving 
mLys367b active, i.e. a negatively charged side chain is absent and the 
cationic lysine cannot be neutralized. The sequence alignment study 
reveals that it is nonconserved (equine position 370b in Figure 1 or 
Figure 3 in [6], see also Tables 6 and 7). Hence in a unique fashion, it 
draws one backbone phosphate group into the agonist position (circle 
“Pag” in Figure 3 in [6]). Another nonconserved position on the outer 
lip of  the MD-2 pocket entry is also involved (equine position 122c 
in Figure 1 here or Figure 3 in [6]). While positively charged lysine 
and arginine stabilize the presence of  a phosphate group in close 
proximity to MD-2, there is a strong repulsion in presence of  murine 
Glu122c. This favors phosphate repositioning – and with it the 
glucosamine backbone of  Lipid IVA – into the agonist site within the 
wedge (circles “Pan” and “Pag” in Figure 3 in [6]). 
In close modeling to the murine and human complexes elucidated 
by x-ray crystallography (Figure 2 and Table 3 in [6] and 
[18,19,21,22,32]), a novel model of a equine TLR4/MD2/ligand 
complex has been generated. As shown in Figure 4, it proposes the 
hitherto unknown dimeric equine complex (eTLR4/eMD-2/Lipid 
IVA)2 with Lipid IVA in an agonistic binding orientation. The 
proposed interface between counterTLR4* (chain b) and MD-2 
(chain c) of the monomeric subunit is found to be consolidated by a 
salt bridge formed between Asp440b and adjacent Arg90c that cannot 
be disrupted (labeled 440b in Figure 1 and labeled 90c in Figure 3, 
see also Tables 6 and 7). Most importantly, the phosphate group 
(P1) of Lipid IVA is bound in the agonist position by side chains of 
the nonconserved – and therefore horse-specific – residues Arg342a, 
Arg385b and Lys389b (Tables 6 and 7). In analogy to the murine 
system, it can be speculated that this may enable the protrusion of at 
least a significant aliphatic part of fatty acid FA1 into the 
TLR4*/MD-2 interface (analog of FA1 of LPS [18]) to stabilize 
this m-shaped dimerization complex by interaction with the reported 
hydrophobic patch exposed on TLR4* [39]. All told, the model 
suggests Lipid IVA acts as agonist in the equine TLR4/MD-2 
system inducing receptor dimerization and signal transduction in the 
innate immune response of the horse. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Docked agonist ligand Lipid IVA into the horse dimeric complex. 
Display and color code: light blue line: backbone of monomer unit (hTLR4 
and hMD-2); sticks (Lipid IVA) in grey, red, and blue colors (atoms H, C, P, 
O, N, respectively); single or double blue dots mark terminal nitrogens of 
monocationic lysine, or arginine, respectively; triple red dots mark the 
three oxygen of monoanionic phosphate groups, double orange dots mark 
the two oxygen of glutamate anion on TLR4* and light blue double dots 
mark the two terminal nitrogens of monocationic arginine on MD-2. All 
carbon atoms of amino acids are colored in dark grey and hydrogen atoms 
are omitted. The three reported amino acids are colored with yellow 
heteroatoms [14]. Anionic Asp440b and cationic Arg90c enter into strong 
electrostatic attraction, forming an additional stabilizing element in the 
TLR4*/MD-2 interface, apparently, a prerequisite for dimerization and 
endotoxic signaling.  
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The general model of the complexes formed by MD-2 and TLR4 
is that of a “wedge” (Figure 3 in [6]). The variable phosphate binding 
sites along the leftmost line of  the wedge have been identified as the 
potential dimerization interface in the prior study of  Meng et al. [14]. 
In a 2010 follow-up publication (with a wrong residue assignment in 
its title: Asp122 instead of  Glu122), the interface of  TLR4/MD-2 
(without TLR4*) with hTyr42c (chain c is MD-2 in [18]) was 
mechanistically analyzed [14]. Hence, it can be assumed that stable 
heterodimers of  TLR4 and MD-2 are present in an a-priori existing 
functional unit on the cell surface. Even though encoded by the 
corresponding individual genes, TLR4 and MD-2 may just be seen as 
two joint domains of  a single ´fusion´ protein because they are 
coordinately expressed and the corresponding high-affinity complex 
has been shown to be pre-assembled in the trans-Golgi network 
during the vesicular transport of  TLR4/MD-2 to the plasma 
membrane [19,22,42]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The hydrophobic cleft of MD-2 displays a characteristic 
asymmetric bi-partite composition: The first, ´lower right´ part of the 
MD-2 cavity is located at the ´primary´(a priori) complexation site 
between MD-2 and TLR4 and contains the deepest and most 
hydrophobic part of the groove accommodating the two (R)-3-
acyloxyacyl units, i.e. fatty acids FA3, 3’, 4 and 4’ attached to the 
GlcN II moiety of LPS/lipid A. The second major part of the cleft is 
located in the opposite direction at the left ´opened´ side near to the 
´secondary´ dimerization zone in the wedge model and represents a 
distinct more hydrophilic substructure within the MD-2 cavity. This 
second major subsite of the MD-2 cleft confers the protrusion of the 
amide-bound ´primary´ 3-hyxdroxymyristoyl residue FA1 - also 
designated as acyl residue “A” in the literature - attached to the GlcN 
I moiety of LPS/lipid A (Figure 3). Since hydrophobic burying of an 
alkyl chain is energetically disfavored in this zone (left side of MD-2) 
this fatty acid chain can apparently protrude without significant 
energetic difference; i.e. partial solvent exposition of FA1 (A) does 
not appear to be more destabilizing than burying it in a nonpolar 
manner within the TLR4/MD-2 single subunit complex. Apparently, 
in presence of another subunit (counter TLR4*/MD-2*) the 
protrusion of this acyl residue becomes even the preferred action. 
Actually, upon the assembly of the active receptor complex protruding 
and interacting with the hydrophobic patch zone on TLR4* 
represents an optimal way of minimizing the repulsive forces between 
this alkyl chain and the surrounding water shell, i.e. “burying” it very 
efficiently in the extended hydrophobic pocket formed by 
TLR4/MD-2 and counter TLR4*, thus forming the bridging 
interface between TLR4/MD-2 and counter TLR4* (left side of the 
wedge in Figure 5). 
 
 
 
 
Inspecting the results of the x-ray structures and modeling-based 
three-dimensional mapping of the species differences in the wedge 
reveals, that only the murine TLR4/MD-2 system possesses two 
Figure 5. Superposition of observed and docked ligand poses into the 
“wedge” with the MD-2 pocket. The cavity surface appears translucent 
and color coded for hydrophilic (grey to bluish) and hydrophobic (green to 
brown) properties. Red or green labels and dots locate favorable (green) 
or unfavorable (red) interactions between the surrounding molecular 
components (Table 1). The backbones of MD-2 and both TLR4 are 
displayed as dark or light blue lines, respectively. The triangular 
interaction zone (“wedge”) is displayed (white dotted lines). The locations 
of the three clustered phosphate binding sites are labeled accordingly: 
TLR4*-attractive “Pag” (green), TLR4-attractive “Pag-Pan” (green), or 
TLR*-repulsive “Pan” (red). Note, the red dots and the red “Pan” label (to 
the left) indicate that the counter TLR4* is rejected while TLR4 stays 
complexed to MD-2 (green labels). The rightmost corner (TLR4-attractive 
“Pag-Pan”) corresponds to the highly conserved phosphate binding site, 
common to all ligands regardless of agonistic or antagonistic activities 
(right corner in Figure 3 in [6]). The labels “F” locate TLR4 / MD-2 
interFaces and their colors indicate the ligand-dependent type of 
interaction: red “F” for repulsion caused by liganded antagonists only, and 
only green “F” for both, agonists and antagonists.   
 
Figure 6. Schematic view of the computed side chain interactions of the 
complete human TLR4 ectodomain/MD-2 complex with Lipid IVA pointing 
out the receptor antagonistic action of Lipid IVA in the human system. 
Note the inverted (flipped) orientation of the sugar-phosphate backbone 
as compared to the agonistic binding of lipid A/LPS to human TLR4/MD-2 
as well as to the agonistic interaction of Lipid IVA with murine TLR4/MD-2 
(see Fig.7). The indicated charged/polar side chains of counter-TLR4* form 
a “repulsion region” that prevents the association of the TLR4/MD-2/Lipid 
IVA unit in the human system. As a direct consequence Lipid IVA does not 
provide the dimerization into an active m-shaped receptor complex in the 
human system and acts as a competitive inibitor of LPS/lipid A (agonist) 
binding instead. Counter-subunit TLR4* is leaving or never was in place, 
which is indicated by the shaded label of TLR4* (upper left side of wedge).    
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attractive (cationic) side chains: lysine and arginine (mLys367b, 
mArg434b (labels 370b and 437b in Figure 1, also Figures 6, 7 and 
8). For this reason in mice, the attraction of the anionic charge of that 
phosphate group is stronger than in the other mammalian species 
compared here. For a ligand (Lig) to become an agonist, the 
occupation of the uppermost phosphate patch which constitutes a 
more TLR4*-exposed area, enables bridging both monomers 
(TLR4/MD-2/Lig and TLR4*/MD-2*/Lig*) to form an active 
dimeric subunit complex (TLR4/MD-2/Lig)2. In addition, in the 
mouse system a lysine side chain (mLys319a, not mLys341a) clearly 
contributes to the phosphate binding of the ligand in the agonist 
position (labels 322a and 344a in Figure 1). The phosphate binding 
site pattern in the wedge zone of the mouse differs mainly from that 
of the other three species because the phosphate is attracted by 
mLys367b whilst the analog horse lysine of counter-TLR4* on chain 
b (eLys389b) is neutralized in a salt bridge. As a sort of 
compensation the ligand moves upward under the influence of the 
very long and branched side chain of eArg90c. 
Concerning agonistic Lipid IVA, in the murine MD-2 acidic 
mGlu122c causes electrostatic repulsion of  the monoanionic 
phosphate group which moves up (to “Pag” in Figure 3 in [6]) while 
the corresponding homo and equus residues 58 and 122 on strand 3 
of  sheet “C” (hLys58c, eArg58c, hLys122c, eArg122c, see also 
Tables 6 and 7) exercise attraction forces on phosphate keeping the 
latter in closer position to the antagonistic site. The cationic side 
chains of  eArg58c and eArg122c are longer than hLys58c and 
hLys122c which reflects that ligand Lipid IVA in human systems lies 
in antagonistic pose with its phosphate group (“P2” in Figure 6)  
located in the lower left corner of  the wedge (“Pan” in Figure 3 in 
[6]) whilst Lipid IVA in equine systems (partial or weak agonism) can 
move into a “in-between” position, that is between human and mouse 
poses in the upper left and lower left corner of  the wedge, respectively 
(Figure 3 in [6], also Figures 4, 5 and 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additional ligand-relevant amino acids of MD-2 were also 
inspected and listed (Tables 6 and 7). The group of mechanistically 
interacting side chains lies on all sides of the wedge between TLR4, 
TLR4* and MD-2 (Table 7). 
Intriguingly, Phe126 of human MD-2 (strand 5 of sheet “B”) 
interacts with TLR4*/MD-2 and was reported by Park et al.: “The 
phenylalanine 126 loop undergoes localized structural change and 
supports this core hydrophobic interface by making hydrophilic 
interactions with TLR4” [18]. In full agreement with Meng et al. our 
binding model also predicts the phosphate attracting role of cationic 
residues in position 122 on human and equine chains c (MD-2), 
whereas glutamate 122c assists the upward shift of the phosphate 
group (Figure 3 in [6] as well as Figure 2) [14]. The listed results 
extend Meng’s report (Tables 6 and 7) [14]. 
Figure 7. Schematic view of the computed side chain interactions of the 
murine TLR4 ectodomain/MD-2 complex with Lipid IVA pointing out the 
agonistic action of Lipid IVA in the mouse system. The repulsive, anionic 
sidechain interaction of a glutamate residue specifically present in murine 
MD-2 (Glu122c) favors the upward shift of the phosphate residue P1 (1-
PO4) at GlcN-I into the bridging position formed by a cluster of residues of 
TLR4, MD-2 and TLR4*. In line with the current consensus model of 
agonist-induced TLR4/MD-2 activation dimerization into the active m-
shaped receptor complex takes place in consequence. 
 
Figure 8. Schematic view of the computed side chain interactions of the 
equine TLR4 ectodomain/MD-2 complex with Lipid IVA indicating the 
(weakly) agonistic action of Lipid IVA in the horse system. The phosphate 
group P1 of the ligand connects the equine TLR4/MD-2 unit with its 
counter-TLR4*. The eMD-2 vestibule is as rich in cationic residues as the 
human one (Figure 6), what reflects the weak agonism in horse. Mainly 
attractive forces of chain “a” arginine (Arg385a) assist the agonistic 
position (left side, phosphate P1 attached to glucosamine GlcN-1) with its 
dimerization propensity.  
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Conclusions 
 
The binding modes were established based on experimental 
observations in the literature and some of the identified residues had 
been reported as species-relevant in earlier mutagenesis studies. In 
contrast to the major natural ligand ´hexa-acyl type´ lipid A present in 
LPS of various commensal and pathogenic Gram-negative bacteria, 
´under-acylated´ precursor or synthetic structures such as Lipid IVA 
or Eritoran represent much more non-natural congeners and thus 
particular ´imperfect´ ligands of mammalian TLR4/MD-2. With 
respect to the human receptor system, both of latter tetra-acylated 
compounds cannot connect TLR4 with counter TLR4* through their 
flipped biphosphorylated diglucosamine backbone and are more 
deeply buried in the MD-2 cavity by about 4 to 5 Å with respect to 
LPS. As described here more in detail for comparison of the human, 
murine and equine TLR4/MD2 complexes, it is save to conclude 
that Lipid IVA constitutes rather an “accidental” agonist or 
antagonist (lower affinity ligand) than an agent with dual activity. As 
an agonist it can bridge the gap between the phosphate binding site of 
TLR4/MD-2 and the counter unit TLR4”. As a flipped antagonist 
it is more deeply buried into MD-2. Only one phosphate group (P1 
of glucosamine GlcN-1) can occupy the more conserved phosphate 
binding location in the lower right corner of the wedge. The other 
phosphate group (P2 of GlcN-2), however, cannot reach the 
phosphate binding site of agonists like LPS, which is composed of 
side chains of counter TLR4* and one variable TLR4 residue. 
Dimerization is then triggered by connecting a TLR4/MD-2 unit to 
the counter TLR4*. Agonistic activity is always associated with 
ligand-brigded dimerization of the TLR4/MD-2 complex. The 
phosphate binding residues between TLR4 and MD-2 in the 
rightmost corner of the wedge model are highly conserved. The 
conservation reflects the need of preserving an optimal grip 
(attraction) on one phosphate group as a “primary” or imperative 
fixation point because its binding always takes place, regardless the 
agonistic or antagonistic nature of the ligands. In contrast, the other 
phosphate location varies due to species-specific changes in the side 
chains from both sides (TLR4, TLR4*) of the wedge. Upon their 
binding agonists lead to a TLR4/MD-2/Lig dimerization in a 
defined m-shaped complex triggering the recruitment of adapter 
proteins to the cytolpasmic TIR domains of the TLR4 subunits and 
in turn the activation of multiple downstream-signaling cascades 
which provide the pro-inflammatory response. The results were 
unambiguously confirmed by newer crystal structures in 2012 (PDB 
codes, 3VQ1 and 3VQ2). 
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